Pfizer announced on Thursday that it is progressing with the development of a once-daily weight loss pill, which it anticipates could be competitive in the GLP-1 market. Meanwhile, the U.S. Food and Drug Administration (FDA) did not approve Novo Nordisk’s once-weekly insulin. Additionally, a report from the U.S. Federal Trade Commission (FTC) indicated that pharmacy benefit managers (PBMs) are contributing to the rising prices of drugs.
